Gossamer Bio Inc
4GB
Company Profile
Business description
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Contact
3013 Science Park Road
Suite 200
San DiegoCA92121
USAT: +1 858 684-1300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
135
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,082.10 | 68.80 | 0.86% |
| CAC 40 | 8,062.41 | 34.13 | 0.43% |
| DAX 40 | 23,043.00 | 56.18 | 0.24% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,654.98 | 22.65 | 0.26% |
| HKSE | 24,145.57 | 185.59 | 0.77% |
| NASDAQ | 17,754.09 | 451.07 | 2.61% |
| Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
| NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
| S&P 500 | 5,638.94 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
| SSE Composite Index | 3,426.13 | 6.57 | 0.19% |